Interleukin-9 stimulates the production of interleukin-5 in CD4+ T cells

European Cytokine Network

Volumn 16, Issue 3, 2005, Pages 233-239

  Poulin, Lionel F ^a   Habran, Claude ^a   Stordeur, Patrick ^a   Goldman, Michel ^a   McKenzie, Andrew ^b   Van Snick, Jacques ^c,d   Renauld, Jean Christophe ^c,d   Braun, Michel Y ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Lymphokine; Rodent; Th2 cells; Transgenic knockout; Transplantation

Indexed keywords

CD3 ANTIBODY; INTERLEUKIN 5; INTERLEUKIN 9; MESSENGER RNA; ALLOANTIGEN; INTERLEUKIN RECEPTOR;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT REJECTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; TH2 CELL; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; DRUG EFFECT; EOSINOPHIL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SPLEEN; TRANSGENIC MOUSE;

MUS; RODENTIA;

ANIMALS; CELLS, CULTURED; EOSINOPHILS; GRAFT REJECTION; INTERLEUKIN-5; INTERLEUKIN-9; ISOANTIGENS; MICE; MICE, TRANSGENIC; RECEPTORS, INTERLEUKIN; SKIN TRANSPLANTATION; SPLEEN; TH2 CELLS;

EID: 33644673058     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Chan SY, Debruyne LA, Goodman RE, Eichwald EJ, Bishop DK. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 1995; 59: 1155.
2. Matesic D, Valuijskikh A, Pearlman E, Higgins AW, Gillima AC, Heeger PS. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells. J Immunol 1998; 161: 5236.
3. Le Moine A, Surquin M, Demoor FX, et al. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. J Immunol 1999; 163: 3778.
4. Le Moine A, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest 1999; 103: 1659.
5. Braun MY, Desalle F, Le Moine A, et al. IL-5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: regulatory role of alloreactive CD8(+) T lymphocytes and IFN-gamma. Eur J Immunol 2000; 30: 1290.
6. Coudert JD, Foucras G, Demur C, et al. Lethal host-versus-graft disease and hypereosinophilia in the absence of MHC I-T-cell interactions. J Clin Invest 2000; 105: 1125.
7. Schmitt E, van Brandwijk R, van Snick I, Siebold B, Rude E. TCGF III/P40 is produced by naive murine CD4+ T cells but is not a general T cell growth factor. Eur J Immunol 1989; 19: 2167.
8. Gessner A, Blum H, Rollinghoff M. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 1993; 189: 419.
9. Uyttenhove C, Simpson RJ, van Schnick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci USA 1988; 85: 6934.
10. Vink A, Warnier G, Brombacher F, Renauld JC. Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population. J Exp Med 1999; 189: 1413.
11. Dong Q, Louahed J, Vink A, et al. IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Eur J Immunol 1999; 29: 2130.
12. Hultner L, Druez C, Moeller J, et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990; 20: 1413.
13. Godfraind C, Louahed J, Faulkner H, et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol 1998; 160; 3989.
14. Holbrook ST, Ohls RK, Schibler KR, Yang YC, Christensen RD. Effect of interleukin-9 on clonogenic maturation and cell-cycle status of fetal and adult hematopoietic progenitors. Blood 1991; 77: 2129.
15. McLane MP, Haczku A, Van de Rijn, et al. Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Am J Respir Cell Mol Biol 1998; 19: 713.
16. Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia. and bronchial hyperresponsiveness. J Exp Med 1998; 188: 1307.
17. Louahed J, Zhou Y, Maloy WL, et al. Interleukin 9 promotes influx and local maturation of eosinophils. Blood 2001; 97: 1035.
18. Temann UA, Ray P, Flavell RA. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest 2002; 109: 29.
19. Gounni AS, Gregory B, Nutku E, et al. Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 2000; 96: 2163.
20. Poulin LF, Richard M, Le Moine A. Interleukin-9 promotes eosinophilic rejection of mouse heart allografts. Transplantation 2003; 76: 572.
21. Kopf M, Brombacher F, Hodgkin PD, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996; 4: 15.
22. Buonocore S, Paulart F, Le Moine, et al. Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood 2003; 101: 1469.
23. Townsend JM, Fallon GP, Matthews JD. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000; 13: 573.
24. Renauld JC, van der Lugt N, Vink A, et al. Thymic lymphomas in interleukin 9 transgenic mice. Oncogene 1994; 9: 1327.
25. Richard M, Grencis RK, Humphreys NE, Renauld JC, van Schnick J. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci USA 2000; 97: 767.
26. Chan WI, Richard M, Akiho H, et al. Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect Immun 2003; 71: 2430.
27. Stordeur P, Poulin LF, Craciun L, et al. Cytokine mRNA quantification by real-time PCR. J Immunol Methods 2002; 259: 55.
28. Arendse B, van Schnick J, Brombacher F. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 2005; 174: 2205.
29. Flamand V, Abramovicz D, Goldman M, et al. Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. J Immunol 1990; 144: 2875.
30. Fallon PG, John HE, Smith P, et al. 1L-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 2002; 17: 7.
31. Zuany-Amorim C, Ruffle C, Haile S, Vargaftig BB, Pereida P, Pretolani M. Requirement for gammadelta T cells in allergic airway inflammation. Science 1998; 280: 1265.
32. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J Immunol 2000; 164: 916.
33. Stadler T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152: 1127.
34. Viard I, Wehrli P, Bullani R, et al. Inhibition of epidermal necrolyis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490.
35. Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to crosslinkage of Fc epsilon RI or to calcium ionophores. Nature 1989; 339: 64.
36. Salvi S, Semper A, Blomberg A, et al. Interleukin-5 production by human airway epithelial cells. Am J Respir Cell Mol Biol 1999; 20: 984.
37. Ryan PJ, Willson T, Alexander WS, Di Rago L, Mifsud S, Metcalf D. The multi-organ origin of interleukin-5 in the mouse. Leukemia 2001; 15: 1248.